Molecular cancer testing of KRAS and miR-21 from EUS-guided biopsies of pancreatic tissue: Utility of aspirates vs. cytology

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F16%3AN0000020" target="_blank" >RIV/26475821:_____/16:N0000020 - isvavai.cz</a>

Result on the web

<a href="http://cancerres.aacrjournals.org/content/76/24_Supplement/B18" target="_blank" >http://cancerres.aacrjournals.org/content/76/24_Supplement/B18</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Molecular cancer testing of KRAS and miR-21 from EUS-guided biopsies of pancreatic tissue: Utility of aspirates vs. cytology

Original language description

Poster at AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; May 12-15, 2016; Orlando, FL. urrently, there is a lack of reliable markers useable in diagnosis and/or management of the pancreatic ductal adenocarcinoma (PDAC). Although detection of KRAS point mutations for the differential diagnosis and determination of miR-21 expression for diagnostic and prognostic purposes have been widely investigated with promising results, neither KRAS nor miR-21 testing have become routine in clinical practice so far. One of the reasons is that analysis of KRAS mutations and miRNA expression is mainly performed on resected pancreatic tissue the use of which is relevant only for a minority of PDAC patients undergoing of surgical treatment. The present study describes development of a reliable methodology for analysis of KRAS mutations and miR-21 expression from samples acquired by endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB), applicable to all PDAC patients. Consequently, the success rates and clinical validity of KRAS mutation and miR-21 expression analysis in two common types of EUS-FNB samples, i.e. native aspirates and cytology specimens are compared. Although both types of EUS-FNB samples are suitable for DNA/RNA extraction and subsequent DNA mutation and miRNA expression analysis, reliable results with clinical validity were only obtained for cytological specimens. Native aspirates exhibit a low and undefined fraction of tumor cells leading to false interpretation of molecular testing results. EUS-FNB samples in the form of cytology specimens are a perspective source for the study of molecular markers in virtually all PDAC patients, including patients in inoperable stages.

Czech name

—

Czech description

—

Type

O - Miscellaneous

CEP classification

EB - Genetics and molecular biology

OECD FORD branch

—

Project

<a href="/en/project/NT13638" target="_blank" >NT13638: The clinical significance of epigenetic factors for improvement of diagnosis, assessment of prognosis and the risk of recurrence after curative resection for pancreatic cancer.</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů